WO2011098060A3 - Therapieoptimierung bei krebspatienten durch austesten von therapiekombinationen mittels in vitro testungen - Google Patents

Therapieoptimierung bei krebspatienten durch austesten von therapiekombinationen mittels in vitro testungen Download PDF

Info

Publication number
WO2011098060A3
WO2011098060A3 PCT/DE2010/001532 DE2010001532W WO2011098060A3 WO 2011098060 A3 WO2011098060 A3 WO 2011098060A3 DE 2010001532 W DE2010001532 W DE 2010001532W WO 2011098060 A3 WO2011098060 A3 WO 2011098060A3
Authority
WO
WIPO (PCT)
Prior art keywords
therapy
cancer patients
testing
vitro tests
combinations
Prior art date
Application number
PCT/DE2010/001532
Other languages
English (en)
French (fr)
Other versions
WO2011098060A2 (de
Inventor
Frank Christian Kischkel
Original Assignee
Frank Christian Kischkel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Frank Christian Kischkel filed Critical Frank Christian Kischkel
Priority to DE112010005241T priority Critical patent/DE112010005241A5/de
Publication of WO2011098060A2 publication Critical patent/WO2011098060A2/de
Publication of WO2011098060A3 publication Critical patent/WO2011098060A3/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Zur Zeit gibt es kein Diagnostikum, welches verschiedene Therapieoptionen für einen Patienten in einem Testsystem bewerten kann. Insbesondere die Einflüsse unterschiedlicher Nährstoffangebote und Sauerstoffangebote (modifiziert durch Ernährung oder Medikamente) auf eine chemotherapeutische Behandlung mit Zytostatika lassen sich heute noch nicht diagnostisch bewerten. Durch Verwendung eines funktionalen Testsystems, welches lebende Tumorzellen in vitro beobachtet, können diese Einflüsse bewertet werden. Insbesondere durch die Reduktion oder das Weglassen von Glukose und /oder Sauerstoff lässt sich dies in den funktionalen Testsystemen erreichen. Dieses Verfahren kann in der gesamten Onkologie verwendet werden.
PCT/DE2010/001532 2010-02-09 2010-12-29 Therapieoptimierung bei krebspatienten durch austesten von therapiekombinationen mittels in vitro testungen WO2011098060A2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE112010005241T DE112010005241A5 (de) 2010-02-09 2010-12-29 Therapieoptimierung bei Krebspatienten durch Austesten von Therapiekombinationen mittels in vitro Testungen

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE201010007243 DE102010007243B4 (de) 2010-02-09 2010-02-09 Therapieoptimierung bei Krebspatienten durch Austesten von Therapiekombinationen mittels in vitro Testungen (Zusatz)
DE102010007243.5 2010-02-09

Publications (2)

Publication Number Publication Date
WO2011098060A2 WO2011098060A2 (de) 2011-08-18
WO2011098060A3 true WO2011098060A3 (de) 2011-11-10

Family

ID=44316549

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2010/001532 WO2011098060A2 (de) 2010-02-09 2010-12-29 Therapieoptimierung bei krebspatienten durch austesten von therapiekombinationen mittels in vitro testungen

Country Status (2)

Country Link
DE (2) DE102010007243B4 (de)
WO (1) WO2011098060A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109999183B (zh) * 2019-04-15 2021-03-09 中国科学技术大学 一种含有乏氧激活前药的纳米簇化酶及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006094716A1 (en) * 2005-03-07 2006-09-14 Johannes Coy Method for ckecking and controlling the mammalian lactic acid fermentation process/aerobic glucose fermentation metabolic pathway in mammalian organism
WO2008118846A1 (en) * 2007-03-23 2008-10-02 Precision Therapeutics, Inc. Methods for evaluating angiogenic potential in culture
WO2008119077A1 (en) * 2007-03-28 2008-10-02 University Of Southern California Induction of differential stress resistance and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006094716A1 (en) * 2005-03-07 2006-09-14 Johannes Coy Method for ckecking and controlling the mammalian lactic acid fermentation process/aerobic glucose fermentation metabolic pathway in mammalian organism
WO2008118846A1 (en) * 2007-03-23 2008-10-02 Precision Therapeutics, Inc. Methods for evaluating angiogenic potential in culture
WO2008119077A1 (en) * 2007-03-28 2008-10-02 University Of Southern California Induction of differential stress resistance and uses thereof

Also Published As

Publication number Publication date
DE102010007243A1 (de) 2011-08-11
DE112010005241A5 (de) 2012-11-15
DE102010007243B4 (de) 2011-11-17
WO2011098060A2 (de) 2011-08-18

Similar Documents

Publication Publication Date Title
MX350781B (es) Anticuerpo anti-humano trop-2 que tiene actividad anti-tumoral in vivo.
WO2014205555A8 (en) Methods and uses for diagnosis and treatment of prostate cancer
WO2013071012A3 (en) Personalized strategic cancer treatment
WO2007136733A3 (en) Mobile radiation therapy
GB201007235D0 (en) Taz/wwtr1 for diagnosis and treatment of cancer
IN2012DN06309A (de)
WO2011112903A3 (en) Quantitative rt-pcr detection for genes involved in epithelial mesenchymal transition in peripheral blood of breast cancer patients
WO2012109466A3 (en) Long non-coding rna spry4-it1 as a diagnostic and therapeutic agent
WO2015158652A3 (en) S1 oop and hyluronic acid as biomarkers for metastatic breast cancer
MX356593B (es) Régimen de tratamiento que utiliza neratinib para cáncer de mama.
TN2012000590A1 (en) Apparatus, method and computer-readable storage medium for evaluating a physiological condition of a patient
WO2011098060A3 (de) Therapieoptimierung bei krebspatienten durch austesten von therapiekombinationen mittels in vitro testungen
IN2012DN02200A (de)
Datta et al. Re: Chou R, Loeser JD, Owens DK, et al. Interventional therapies, surgery, and interdisciplinary rehabilitation for low back pain: an evidence-based clinical practice guideline from the American Pain Society. Spine 2009; 34: 1066–77
WO2013182905A3 (en) Mechanism, diagnostic, and treatments for complications of renal failure
Shields et al. Cancer-related fatigue in gynecologic oncology patients undergoing chemotherapy
Kim et al. Change of subtype in patients with advanced breast cancer after neoadjuvant chemotherapy
李志军 The Clinical Application of TACE combined with PEI and RF on Treatment of Hepatocellular Carcinoma
UA57559U (ru) Способ определения и коррекции психоэмоционального состояния беременных женщин
Um et al. Nutritional Assessment and Nutritional Management for GI Cancer Patients
UA54725U (ru) Способ определения переносимости лекарственных средств при проведении первой фазы клинических исследований и исследовании биоэквивалентности
徐徕 Impact of neoadjuvant chemoradiation on perineal wound healing after abdominoperineal resection for lower rectal cancer
Cole Cancer expert doubts claims about prostate cancer trial
Denys et al. 2010 IMPAKT Breast Cancer Conference
Moyer Imatinib Shown Effective for Dermatofibrosarcoma Protuberans

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10841802

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 112010005241

Country of ref document: DE

Ref document number: 1120100052417

Country of ref document: DE

REG Reference to national code

Ref country code: DE

Ref legal event code: R225

Ref document number: 112010005241

Country of ref document: DE

Effective date: 20121115

122 Ep: pct application non-entry in european phase

Ref document number: 10841802

Country of ref document: EP

Kind code of ref document: A2